BN

Bharat Nathalal Shah

Active Director Director DIN 07467629
DIN 07467629 First appointment Mar 2016 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2016
Shareholding value •••• Premium profile

About Bharat Nathalal Shah

Data last updated:

Bharat Nathalal Shah is a Director at M I Pharma Private Limited (since 2016). The company operates in Pharma. M I Pharma Private Limited reported revenue of ₹3.47 Cr (FY 2025).

DIN 07467629
Primary Designation Director
Industry Pharma
First Appointment 16 Mar 2016
Oldest Company Age 17 yrs
Largest company M I Pharma Private Limited · ₹3.47 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
M I Pharma Private Limited U24239MH2009PTC190502
Director16 Mar 20162009₹3.47 Cr (FY 2025)Active

Board colleagues of Bharat Nathalal Shah

Directorship timeline

Open interactive timeline →
M I Pharma Private Limited
Premium access

Shareholding and investment profile for Bharat Nathalal Shah

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bharat Nathalal Shah

Bharat Nathalal Shah currently holds 1 directorship: M I Pharma Private Limited (Director, since 16 Mar 2016, revenue ₹3.47 Cr (FY 2025)).

Bharat Nathalal Shah was first appointed on 16 Mar 2016 as Director at M I Pharma Private Limited.

The current boards of Bharat Nathalal Shah's companies include Neeta Bharat Shah (M I Pharma Private Limited), Rajiv Kumar Sharma (M I Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available